title: Flow cytometric crossmatching and outcome one year after renal transplantation.
abstract: Previous studies have shown that flow cytometric crossmatch assays can identify an at risk population in renal transplantation. We used the assay for recipient selection for 1 year. Recipients with donor T cell directed IgG were excluded from transplantation and those with B cell directed IgG were treated with increased immunosuppression. The transplants performed over this period (n = 126) were compared with an earlier series (n = 118) in which flow cytometric crossmatch results did not influence patient management. The results were evaluated for mortality and graft outcome at 3 months and 1 year. In addition, postoperative complications and duration of hospital stay were also assessed.
authors: Department of Surgery, The Medical School, University of Newcastle upon Tyne.
authors: D
authors: D
authors: Talbot
authors: B K
authors: BK
authors: Shenton
authors: A L
authors: AL
authors: Givan
authors: G
authors: G
authors: Cavanagh
authors: G
authors: G
authors: Proud
authors: R M
authors: RM
authors: Taylor
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D005434:Flow Cytometry / Q000379:methods; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3